Home
This Title All WIREs
WIREs RSS Feed
How to cite this WIREs title:
WIREs Nanomed Nanobiotechnol
Impact Factor: 6.14

The consolidation of nanomedicine

Full article on Wiley Online Library:   HTML PDF

Can't access this content? Tell your librarian.

Abstract Over the past two decades, nanomedicine has grown steadily, however, without inducing a palpable shift in the diagnosis and treatment of diseases so far. While this may simply be a consequence of the slow, incremental nature that characterizes many modern technologies, this article posits that there is another set of significant factors harboring explanatory power. Uncertainties concerning safety, regulatory, and ethical requirements may have prompted innovators to stay close to the known and approved, eventually at the cost of innovating in unexplored alleys. Network analysis of all nanomedicine patents in the United States reveals that nanomedicine has indeed rather consolidated than expanded. We detail a set of recommendations that would reduce the uncertainty prevailing in nanomedicine and could contribute to pushing new boundaries. This article is categorized under: Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine
Evolution of US patents in nanomedicine (by year of filing 1972–2016)
[ Normal View | Magnified View ]
Network of nanomedicine patents prior art. (a) 1974–1990; (b) 1974–1995; (c) 1974–2000; (d) 1974–2016. The networks depict nanomedicine patents and their cited patents as nodes. Edges are established by citations. () Nanomedicine patents; () non‐nanomedicine patents
[ Normal View | Magnified View ]

Browse by Topic

Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

The latest WIREs articles in your inbox

Sign Up for Article Alerts